Immune Aspects of Biopharmaceuticals and Nanomedicines

Content: Cover
 Half Title
 Title Page
 Copyright Page
 Dedication
 About the Editors
 Table of Contents
 List of Corresponding Authors
 Foreword
 My Life with Biologicals and Nanodrugs: A Twenty-Year Affair
 1: Current Immune Aspects of Biologics and Nanodrugs: An Overview
 1.1 Introduction
 1.2 Biologics versus Small-Molecule Drugs
 1.3 What Are Nanodrugs?
 1.4 Are Biologics and Nanodrugs Adversely Immunogenic?
 1.5 Immunogenicity Assessment of Biologics and Nanodrugs
 1.6 Entering the Era of Biosimilars
 1.7 Immune Aspects of Biosimilars and Nanosimilars: The Copaxone® Example 1.8 Concluding Remarks and Future Directions2: Immunological Issues with Medicines of Nano Size: The Price of Dimension Paradox
 2.1 Adverse Immune Effects of Nanodrugs
 2.2 Issues of Terminology
 2.3 Adverse Immune Effects of Nanodrugs: The Dimension Paradox
 2.4 Vicious Cycle between Specific and Nonspecific Immune Responses to Nanodrugs
 2.5 CARPA as Blood Stress
 2.6 CARPA Testing
 3: Immunotherapy and Vaccines
 3.1 Introduction
 3.2 The Immune System
 3.3 Nanotechnology in Vaccines
 3.4 Conclusions
 4: Site-Specific Antibody Conjugation for ADC and Beyond
 4.1 Introduction 4.2 Site-Specific ADC through Specific Amino Acids4.3 Site-Specific ADC through Unnatural Amino Acids
 4.4 Site-Specific ADC through Glycans
 4.5 Site-Specific ADC through Short Peptide Tags
 4.6 Site-Specific Antibody Conjugation for Diagnosis
 4.7 Site-Specific Antibody Conjugation for Other Therapeutic Applications
 4.8 Conclusions
 5: Current Understanding of Interactions between Nanoparticles and the Immune System
 5.1 Introduction
 5.2 Achievements
 5.3 Disappointments
 5.4 Lessons Learned
 5.5 Conclusions
 6: Auto-antibodies as Biomarkers for Disease Diagnosis
 6.1 Introduction 6.2 Auto-antibodies as Biomarkers6.3 Auto-antibodies for Companion Diagnostics Enabling Personalized Medicine
 6.4 Biomarker Discovery Strategies
 6.5 Antigen/ Auto-antibody Interactions as Biomarker Candidates
 6.6 Diagnostic Assays Based on Antigen/ Auto-antibody Interactions
 6.7 Conclusion
 7: The Acceleated Blood Clearance Phenomenon of PEGylated Nanocarriers
 7.1 Introduction
 7.2 Mechanism of ABC Phenomenon
 7.3 Correlation Between Complement Activation and ABC Phenomenon
 7.4 Factors That Affect the Magnitude of the ABC Phenomenon 7.5 Strategies to Abrogate/ Attenuate Induction of the ABC Phenomenon7.6 Clinical Implications of ABC Phenomenon
 7.7 Conclusion
 8: Anti-PEG Immunity Against PEGylated Therapeutics
 8.1 Introduction
 8.2 PEG Immunogenicity in Animal Models
 8.3 PEG Immunogenicity in Humans
 8.4 Properties of Anti-PEG Antibody Epitope
 8.5 Strategies to Avert Anti-PEG Antibody Responses
 8.6 Conclusion
 9: Complement Activation: Challenges to Nanomedicine Development
 9.1 Introduction
 9.2 C Activation Pathways and Downstream Effectors
 9.3 Role of C in Human Health and Disease